Global Measurable Residual Disease Testing Market Growth (Status and Outlook) 2023-2029

Global Measurable Residual Disease Testing Market Growth (Status and Outlook) 2023-2029

The global Measurable Residual Disease Testing market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Measurable Residual Disease Testing is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Measurable Residual Disease Testing is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Measurable Residual Disease Testing is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Measurable Residual Disease Testing players cover Adaptive Biotechnologies Corporation, ArcherDX, Inc. (Invitae Corporation), Asuragen, Arup Laboratories, Bio-Rad Laboratories, Cergentis B.V., F. Hoffmann- La Roche Ltd, Guardant Health and ICON plc, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

Measurable residual disease (also known as “minimal residual disease”) refers to the number of cancer cells that remain during and after cancer treatment. Complete remission (less than 5% blasts in bone marrow) by morphologic assessment is not enough to accurately depict remaining malignant cells.

LPI (LP Information)' newest research report, the “Measurable Residual Disease Testing Industry Forecast” looks at past sales and reviews total world Measurable Residual Disease Testing sales in 2022, providing a comprehensive analysis by region and market sector of projected Measurable Residual Disease Testing sales for 2023 through 2029. With Measurable Residual Disease Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Measurable Residual Disease Testing industry.

This Insight Report provides a comprehensive analysis of the global Measurable Residual Disease Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Measurable Residual Disease Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Measurable Residual Disease Testing market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Measurable Residual Disease Testing and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Measurable Residual Disease Testing.

This report presents a comprehensive overview, market shares, and growth opportunities of Measurable Residual Disease Testing market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Flow Cytometry
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Other

Segmentation by application
Hematological Malignancies
Leukemia
Lymphoma
Solid Tumors
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Adaptive Biotechnologies Corporation
ArcherDX, Inc. (Invitae Corporation)
Asuragen
Arup Laboratories
Bio-Rad Laboratories
Cergentis B.V.
F. Hoffmann- La Roche Ltd
Guardant Health
ICON plc
Invivoscribe
Laboratory Corporation of America Holdings
Mission Bio
Natera, Inc.
NeoGenomics Laboratories
Opko Health
Quest Diagnostics Incorporated
Sysmex Corporation
Genetron Health

Please note: The report will take approximately 2 business days to prepare and deliver.